The ABCA1 transporter is one of the limiting steps in cellular cholesterol efflux.
SUMMARY
The ABCA1 transporter is one of the limiting steps in cellular cholesterol efflux.
To study the expression and activity of the human ABCA1 gene in vivo we have examined mice containing two human BAC transgenes with different 5' end. Mice containing a 255 kb BAC transgene, including 70 kb upstream of the previously defined exon 1, demonstrated a pattern of tissue specific expression mimicking that of the endogenous mouse gene. Compared to macrophages from control mice, macrophages from these transgenics had increases in apoA-I cholesterol efflux heightened in response to increases in cell cholesterol content. The observed increase in macrophage apoA-I mediated cholesterol efflux was not accompanied by alterations in plasma HDL in the transgenics. Mice containing a smaller 171 kb human BAC transgene, lacking the previously described exon 1 and ABCA1 promoter, while not expressing human ABCA1 in macrophages, did express the human transgene in liver at levels comparable to that of the orthologous mouse gene. Analysis by 5' RACE of liver mRNA from these animals revealed a new ABCA1 exon 1 (exon 1A) and a previously unrecognized promoter.
Analysis of human tissue revealed that exon 1A containing transcripts accounted for a high proportion of the ABCA1 mRNAs present in human liver. This analysis of ABCA1 transgenics has shown that expression of human ABCA1 transgenes can result in increased cholesterol efflux from macrophages unaccompanied by changes in plasma HDL and has identified a new ABCA1 promoter in humans.
INTRODUCTION
A major mechanism postulated to contribute to the athero-protective effects of high plasma HDL is reverse cholesterol transport. This is a process whereby HDL participates in the transfer of excess cholesterol from peripheral tissues to the liver for catalysis (1, 2) . Specifically HDL is believed to protect against the accumulation of lipids in the vasculature by removing cholesterol and phospholipids through an active transport pathway (3, 4) . This pathway is impaired in Tangier disease (5-7), a rare recessive disorder characterized by the accumulation of lipids in peripheral tissues, dramatic reductions in plasma HDL, and an increased risk for cardiovascular disease (8, 9) . Recent studies have demonstrated that ABCA1, an ATP binding cassette transporter, plays a key role in the apolipoprotein mediated cholesterol transport (10) and that mutations in the ABCA1 gene are the underlying genetic defect in Tangier disease (11) (12) (13) (14) (15) . These results imply that the ABCA1 transporter is a rate-limiting factor in reverse cholesterol transport and plays a key role in the protection against atherosclerosis.
Due to ABCA1's importance in HDL formation and cholesterol efflux, great efforts have been made in defining the genetic components and the cellular mediators determining ABCA1 expression levels. Various in vitro (10, (16) (17) (18) and in vivo (19) studies of ABCA1 expression have shown that this gene is tightly regulated by the cholesterol status of the cell. Studies have defined the human ABCA1 promoter as spanning nucleotides -200 to -80, upstream of exon 1 (20) . This promoter contains a DR-4 element that binds LXR and RXR hetero-dimers and transactivates gene expression when bound to oxysterols and retinoic acid (21-23). This mechanism explains in part the tight regulation of ABCA1 gene by sterols and supports idea that the response of ABCA1 to increased cholesterol leads to an accelerated clearance of cholesterol by macrophages maintaining intracellular cholesterol homeostasis.
While both mice and humans with reduced ABCA1 have been characterized, and shown to have reduced HDL levels and decreased cellular cholesterol efflux (8, 11, (24) (25) (26) (27) , the in vivo effect of increased expression of this gene and its regulation have not been characterized. Accordingly, we have examined transgenic mice with two different human ABCA1 containing BAC transgenes. The mice with the human ABCA1 transgene with more human 5' DNA demonstrated largely appropriated regulation of the human ABCA1 transgene. Surprisingly, the increased cholesterol efflux in macrophages was not accompanied by changes in plasma HDL levels. Analysis of the mice with a 5' truncated ABCA1 transgene led to the discovery of a new ABCA1 promoter and alternatively spliced transcript that is present at high levels in the livers of humans.
EXPERIMENTAL PROCEDURES
Mice-The ABC1 transgenics examined in this study were created and maintained in a pure FVB background as described previously (28). The structure of the 2 BAC transgenes analyzed in this study is depicted in Figure 1 . Both BAC1 and BAC2 encode the complete ABCA1 protein including the ATG methionine initiation site present in exon 2. Expression analysis of human and mouse ABCA1-Total murine RNAs from lung, liver, spleen, proximal, medial and distal small intestine and testis were extracted using the TRIZOL method (Gibco BRL, cat#15596). Total RNA from human tissues including liver, heart, lung, kidney, adrenal, intestine, brain and testis were purchased from Clontech. Reverse transcriptions were performed using 5 ug of total RNA, random hexamers (NE Biolabs) and Superscript II reverse transcriptase (Gibco BRL) at 42°C for 60 min. The amount of cDNA generated was measured using the TaqMan Syber-green quantitative PCR assay with a 7700 ABI PRISM Sequence Detector System (Perkin Elmer-Applied Biosystems). The primer pairs used to detect the mouse endogenous Abca1 gene (mouse exon 2F and mouse exon 4R), the human ABCA1 transgene (exon 3F and exon 4R), the human exon 1A transcript (exon 1AF and exon 2R), and the human exon 1 transcript (exon 1F and exon 2R) are listed in Table 1 . The relative amount of ABCA1 transcript was normalized to 18S RNA amplification values retrieved from the 6 same sample. The control 18S RNA used to correct for total RNA amounts in each sample were purchased from AMBION and a ratio of 0.8/1.2 for primers/competimers was used for all the samples. PCR was performed with an initial hot start of 3 minutes at 94 °C followed by 40 cycles of 94 °C for 10 sec, 57 °C for 15 sec and 72 °C for 30 sec. min) to remove cellular debris and the supernatant was used to measure 3 [H]-cholesterol in the medium. Cell lipids were extracted using isopropanol and efflux results expressed as a % of initial cellular 3 [H] appearing in the medium at each time point.
Isolation of peritoneal macrophages-

5' Rapid Amplification of cDNA Ends (5' RACE)-5' RACE was performed to determine
the 5' end of the human ABCA1 transgene expressed in mouse liver. Total RNAs from the liver tissue of the BAC2 transgenic mouse were extracted using the TRIZOL method (Gibco, BRL). First-strand cDNA was generated from 1 ug of total RNA using Superscript reverse transcriptase (Gibco, BRL) at 42 °C for 60 min. An aliquot of the first strand cDNA was then amplified using a human ABCA1 specific primer Exon 4R (Table 1) Plasma HDL-cholesterol-Background for studying the effect of the increased ABCA1 expression on plasma HDL in the transgenics were studies demonstrating that decreased activity of ABCA1 results in dramatic reductions in plasma HDL in mice (25-27) and humans (8, 11, 24) . The effect of the increased cholesterol efflux noted in isolated macrophages from the BAC1 transgenic mice on plasma HDL in these animals was assessed. Plasma HDL cholesterol in transgenic and control mice on chow and western diet was measured and no significant differences were noted on either diet ( Figure 5 ). 
RESULTS
Expression of human ABCA1 in mouse tissues-
5' RACE-
